In a reverse merger, private firms become publicly traded by merging with a publicly listed shell company, with
the public company surviving.2 In a merger, it is common for the surviving firm to be viewed as the acquirer, since
its shareholders usually end up with a majority ownership stake in the merged firms; the other party to the merger is
viewed as the target firm as its former shareholders often hold only a minority interest in the combined companies.
In a reverse merger, the opposite happens. Even though the publicly traded company survives the merger with the
private firm becoming its wholly-owned subsidiary, the former shareholders of the private firm end up with a
majority ownership stake in the combined firms.
While conventional IPOs can take months to complete, reverse mergers can take only a few weeks. Moreover, as
the reverse merger is solely a mechanism to convert a private company into a public entity, the process is less
dependent on financial market conditions because the company often is not proposing to raise capital. The cost of
regulatory filings and approvals is less with reverse mergers than with IPOs. Finally, firms lacking in historical
financial statements often find the reverse merger as the only practical option.
Early in 2015, biotech firm Tobira Therapeutics went public through a reverse merger after its IPO fizzled. This
successful reverse merger seemed to pave the way for more deals such as Catalyst and Targacept in May 2015 using
a reverse merger to form Catalyst Biosciences.
Existing Miragen shareholders, as well as those in the concurrent financing (so-called PIPE investment), receive
newly issued shares of Signal common stock. Signal’s board of directors approved a 1–for-15 reverse stock split of
its common stock, which took effect immediately following the close of trading on the NASDAQ on November 4,
2016. The reverse stock split is being implemented by Signal to maintain the listing of its common stock on the
NASDAQ.3
The motivation for the merger reflected Miragen’s promising micro RNA therapeutics programs, its limited
resources to fully develop these programs, and its desire to have its shares publicly listed. In contrast, publicly
traded Signal was prepared to raise cash by selling its proprietary technology and issuing new shares through a
private placement.
2 Alternatively, the private firm may merge with an existing special-purpose acquisition company already registered
for public stock trading.
3 Signal had received a deficiency notice from NASDAQ in November 2015 as its stock was trading at about $.33
per share; the reverse split was undertaken to comply with the minimum bid requirement rule of the exchange. To be
in compliance, the closing bid price of Signal’s common stock must be at least $1.00 per share for a minimum of 10